Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...

Daiichi Sankyo and MSD (Merck & Co) have reported that the Phase III HERTHENA-Lung02 clinical trial of patritumab deruxtecan, ...

As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up awareness of the drug among its expanded patient pool. To that end ...

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

No longer a far-off futuristic idea, artificial intelligence technology has seen its popularity skyrocket in recent years. | ...

Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in ...

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumab deruxtecan, for treating EGFR-mutated non-small cell lung ...

Merck & Co., Inc. (MRK) and Daiichi Sankyo (DSKYF.PK) announced that an interim analysis of the dose-optimization phase of the ...

MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, boosting plans to take a second shot at FDA approval. But two more ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in ...